Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3626 Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy

Introduction: PRRT has shown favourable results in NETs. Long-term safety and efficacy data for 177Lu-Octreotate PRRT, particularly in combination with chemotherapy, is lacking.

Conference:

Presenting Author: Ransom D

Authors: Ransom D, Kennedy K, Turner J, Macdonald W, Boardman G,

Keywords: PRRT, long term, chemotherapy, leukaemia, myelodysplasia, renal,

#3578 Optimal PLAnning of treatment and research of Neuroendocrine Tumors (NETs) in Australia: The PLANET registry and patient reported outcomes via PLANET App

Introduction: Neuroendocrine Neoplasms (NENs) are challenging to diagnose and manage due to their varied behaviour. Despite usually having an indolent course, they are often metastatic at diagnosis and can be associated with significant long-term morbidity and impaired quality-of-life (QOL). The PLANET registry was established to collate clinical data from tertiary NET centres and integrate these with real-time patient reported outcomes (PROs) enabled by the smartphone-based PLANET App.

Conference:

Presenting Author: Leyden S

Authors: Leyden S, Cummins M, Pavlakis N, Ransom D, Price T,

Keywords: data, PROMS, PROs, QOLs, real-world data,

#2919 Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II Studies of Lu-Octreotate Peptide Receptor Radionuclide Therapy (LuTate PRRT) +/- Capecitabine, Temozolomide (CAPTEM) or CAPTEM Alone for Neuroendocrine Tumours (NETs

Introduction: Chemotherapy is often combined with PRTT to treat NETs of pancreatic or midgut origin (pNET/mNET) based on the principle of radiosensitization.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Pavlakis N

Authors: Pavlakis N, Ransom D, Wyld D, Sjoquist K, Asher R,

Keywords: Lutate, PRRT, chemotherapy, CAPTEM, NETs,